Cytotheryx, a preclinical-stage cell therapy firm originating from the Mayo Clinic, has closed a $60 million Series A funding round. Led by the Ouroboros Family Founders Fund I, this capital infusion highlights growing investor confidence in scalable cell-based solutions for chronic and acute liver conditions.
Technological differentiation The investment centers on Cytotheryx’s proprietary bio-incubator platform, which offers a unique approach to liver disease management through:
-
Functional cell production: The ability to generate high-quality, scalable human hepatocytes for therapeutic use.
-
Clinical applications: Development of bioartificial liver support systems for acute failure and universal donor cells for transplantation.
Strategic roadmap for 2026 The company plans to utilize the $60 million, alongside additional debt financing, to achieve several key milestones:
-
Infrastructure expansion: Enhancing physical footprints and upgrading Good Manufacturing Practice (GMP) capabilities to meet regulatory standards.
-
Clinical transition: Accelerating lead research programs toward human clinical trials and streamlining regulatory submission pathways.
-
Strategic guidance: Ouroboros will provide advisory support throughout the development lifecycle to maximize the platform’s commercial viability.
Despite a complex venture capital environment for biotech, this funding round underscores the high demand for differentiated cell and gene therapy platforms that address significant unmet medical needs in hepatology.